PharmaEngine

PharmaEngine Revenue per Share

The Revenue per Share of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 6.43 TWD. In the previous year, Revenue per Share was 17.56 TWD — a change of -63.37% (lower).

Revenue per Share

6.43TWD

YoY

-63.37%

Last updated:

Revenue per Share of PharmaEngine is 2025 6.43 TWD. Revenue per Share of PharmaEngine was 2024 17.56 TWD. It decreases by -63.37% lower compared to the previous year.

The PharmaEngine Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2020
7.47 TWD
Jan 1, 2021
4.57 TWD
Jan 1, 2022
4.55 TWD
Jan 1, 2023
5.34 TWD
Jan 1, 2024
17.56 TWD
Jan 1, 2025
6.43 TWD
Jan 1, 2026 (e)
7.14 TWD
Jan 1, 2027 (e)
0.00 TWD
The PharmaEngine Revenue per Share history
YEARRevenue per ShareYoY
est0.00TWD-100.00%
est7.14TWD+10.97%
6.43TWD-63.37%
17.56TWD+228.54%
5.34TWD+17.39%
4.55TWD-0.27%
4.57TWD-38.86%
7.47TWD+251.78%
2.12TWD+7.38%
1.98TWD-58.77%
4.79TWD-38.15%
7.75TWD+124.87%
3.45TWD+117.26%
1.59TWD+467.80%
0.28TWD-82.48%
1.60TWD-41.12%
2.71TWD—
0.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Revenue per Share of PharmaEngine is 6.43 TWD in 2025.

Revenue per Share of PharmaEngine changed from 17.56 TWD to 6.43 TWD, representing a -63.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PharmaEngine

All Key Metrics — PharmaEngine